je.st
news
Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...
2015-05-30 21:49:00| Logistics - Topix.net
Clovis Oncology today announced updated Phase 2 results from two ongoing clinical studies with rucaparib: ARIEL2 and Study 10. Rucaparib is the Company's investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of advanced ovarian cancer, specifically in patients with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as "BRCA-like." Updated data from the ARIEL2 study in 204 patients with advanced ovarian cancer are being presented Monday in an oral presentation by Professor Iain McNeish at the 2015 American Society of Clinical Oncology annual meeting in Chicago.
Tags: studies
phase
cancer
ovarian
Category:Transportation and Logistics
Latest from this category |
All news |
||||||||||||||||||
|
|||||||||||||||||||